Ptc Therapeutics Stock Current Valuation
| PTCT Stock | USD 42.89 0.93 2.22% |
Valuation analysis of PTC Therapeutics helps investors to measure PTC Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 3.9 B in 2024, whereas Enterprise Value Over EBITDA is likely to drop (11.75) in 2024. Fundamental drivers impacting PTC Therapeutics' valuation include:
Price Book 1.7 K | Enterprise Value 2.4 B | Enterprise Value Ebitda (10.22) | Price Sales 3.5931 | Enterprise Value Revenue 2.6897 |
Overvalued
Today
Please note that PTC Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of PTC Therapeutics is based on 3 months time horizon. Increasing PTC Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
PTC Therapeutics' intrinsic value may or may not be the same as its current market price of 42.89, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 42.89 | Real 37.9 | Target 35.42 | Hype 42.36 | Naive 39.56 |
The intrinsic value of PTC Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence PTC Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of PTC Therapeutics helps investors to forecast how PTC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PTC Therapeutics more accurately as focusing exclusively on PTC Therapeutics' fundamentals will not take into account other important factors: PTC Therapeutics Company Current Valuation Analysis
PTC Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current PTC Therapeutics Current Valuation | 2.42 B |
Most of PTC Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PTC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PTC Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for PTC Therapeutics is extremely important. It helps to project a fair market value of PTC Stock properly, considering its historical fundamentals such as Current Valuation. Since PTC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PTC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PTC Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
PTC Current Valuation Historical Pattern
Today, most investors in PTC Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various PTC Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of PTC Therapeutics current valuation as a starting point in their analysis.
PTC Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, PTC Therapeutics has a Current Valuation of 2.42 B. This is 83.13% lower than that of the Biotechnology sector and 47.85% lower than that of the Health Care industry. The current valuation for all United States stocks is 85.43% higher than that of the company.
PTC Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PTC Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PTC Therapeutics could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics of similar companies.PTC Therapeutics is currently under evaluation in current valuation category among its peers.
PTC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.8B | 4.0B | 2.8B | 2.7B | 2.1B | 1.3B | |
| Enterprise Value | 2.5B | 4.2B | 2.5B | 3.0B | 3.7B | 3.9B |
PTC Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PTC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PTC Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
PTC Fundamentals
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0515 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 2.42 B | ||||
| Shares Outstanding | 77.13 M | ||||
| Shares Owned By Insiders | 2.34 % | ||||
| Shares Owned By Institutions | 97.66 % | ||||
| Number Of Shares Shorted | 4.89 M | ||||
| Price To Earning | (5.67) X | ||||
| Price To Book | 1,743 X | ||||
| Price To Sales | 3.59 X | ||||
| Revenue | 937.82 M | ||||
| Gross Profit | 2.63 M | ||||
| EBITDA | (330.34 M) | ||||
| Net Income | (626.6 M) | ||||
| Cash And Equivalents | 288.43 M | ||||
| Cash Per Share | 4.01 X | ||||
| Total Debt | 2.23 B | ||||
| Current Ratio | 1.23 X | ||||
| Book Value Per Share | (13.70) X | ||||
| Cash Flow From Operations | (158.42 M) | ||||
| Short Ratio | 5.83 X | ||||
| Earnings Per Share | (5.94) X | ||||
| Price To Earnings To Growth | 0.81 X | ||||
| Target Price | 45.0 | ||||
| Number Of Employees | 988 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 3.24 B | ||||
| Total Asset | 1.9 B | ||||
| Retained Earnings | (3.28 B) | ||||
| Working Capital | 615.53 M | ||||
| Current Asset | 355.95 M | ||||
| Current Liabilities | 45.39 M | ||||
| Net Asset | 1.9 B |
About PTC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.